1 Clinical Microbiology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU2 Statens Serum Institut3 Odense University Hospital4 Public Health and Research Institute, Rutgers University, Newark, New Jersey, USA.5 Mycology Unit, Statens Serum Institut, Copenhagen, Denmark firstname.lastname@example.org Clinical Microbiology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU
Echinocandins are the preferred therapy for invasive infections due to Candida krusei. We present here a case of clinical failure involving C. krusei with a characteristic FKS1 hot spot mutation not previously reported in C. krusei that was isolated after 14 days of treatment. Anidulafungin MICs were elevated by ≥5 dilution steps above the clinical breakpoint but by only 1 step for a Candida albicans isolate harboring the corresponding mutation, suggesting a notable species-specific difference in the MIC increase conferred by this mutation.
Antimicrobial Agents and Chemotherapy, 2014, Vol 58, Issue 6, p. 3550-3552